Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination.

Perineural invasion and neurogenesis are frequently observed in pancreatic ductal adenocarcinoma (PDAC), and they are associated with a poor prognosis. Axon guidance factor semaphorin 3A (SEMA3A) is upregulated in PDAC. However, it remains unclear whether cancer-derived SEMA3A influences nerve innervation and pancreatic tumorigenesis. In silico analyses were performed using PROGgene and NetworkAnalyst to clarify the importance of SEMA3A and its receptors, plexin A1 (PLXNA1) and neuropilin 2 (NRP2), in pancreatic cancer. In vitro assays, including migration, neurite outgrowth, and 3D recruitment, were performed to study the effects of SEMA3A on neuronal behaviors. Additionally, an orthotopic animal study using C57BL/6 mice was performed to validate the in vitro findings. Expression of SEMA3A and its receptors predicted worse prognosis for PDAC. Cancer-derived SEMA3A promoted neural migration, neurite outgrowth, and neural recruitment. Furthermore, SEMA3A-induced effects depended on PLXNA1, NRP2, and MAPK activation. Trametinib, an approved MAPK kinase (MEK) inhibitor, counteracted SEMA3A-enhanced neuronal activity in vitro. Inhibition of SEMA3A by shRNA in pancreatic cancer cells resulted in decreased neural recruitment, tumor growth, and dissemination in vivo. Our results suggested that cancer-secreted SEMA3A plays an important role in promoting neo-neurogenesis and progression of PDAC.

[1]  M. Fujishiro,et al.  The Role of Neural Signaling in the Pancreatic Cancer Microenvironment , 2022, Cancers.

[2]  Megumi Watanabe,et al.  Semaphorin 3A: A potential target for prevention and treatment of nickel allergy , 2022, Communications Biology.

[3]  K. Kuwako,et al.  Molecular mechanisms regulating the spatial configuration of neurites. , 2022, Seminars in cell & developmental biology.

[4]  A. Maitra,et al.  Translational advances in pancreatic ductal adenocarcinoma therapy , 2022, Nature Cancer.

[5]  W. Hung,et al.  Semaphorin 6C Suppresses Proliferation of Pancreatic Cancer Cells via Inhibition of the AKT/GSK3/β-Catenin/Cyclin D1 Pathway , 2022, International journal of molecular sciences.

[6]  Jing Deng,et al.  Semaphorin 3A attenuates the hypoxia suppression of osteogenesis in periodontal ligament stem cells. , 2022, Journal of periodontal research.

[7]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[8]  Y. Tien,et al.  Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry , 2021, Annals of Surgical Oncology.

[9]  Kenji Tsuji,et al.  Semaporin3A-inhibitor ameliorates renal fibrosis through the regulation of JNK signaling. , 2021, American journal of physiology. Renal physiology.

[10]  C. Jiang,et al.  Tumor innervation and clinical outcome in pancreatic cancer , 2021, Scientific Reports.

[11]  K. Ishido,et al.  Roles of the nervous system in pancreatic cancer , 2021, Annals of gastroenterological surgery.

[12]  Hua You,et al.  Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer , 2021, Theranostics.

[13]  A. Koong,et al.  Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer , 2020, Clinical Cancer Research.

[14]  L. You,et al.  Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? , 2020, Frontiers in Oncology.

[15]  M. O'Hara,et al.  Challenges and Opportunities for Pancreatic Cancer Immunotherapy. , 2020, Cancer cell.

[16]  M. Kano,et al.  Influences of Semaphorin 3A Expression on Clinicopathological Features, Human Papillomavirus Status, and Prognosis in Oropharyngeal Carcinoma , 2020, Microorganisms.

[17]  Kenji Tsuji,et al.  Semaphorin3A-Inhibitor Ameliorates Doxorubicin-Induced Podocyte Injury , 2020, International journal of molecular sciences.

[18]  G. Tang,et al.  Synthesis of some new acylhydrazone compounds containing the 1,2,4-triazole structure and their neuritogenic activities in Neuro-2a cells , 2020, RSC advances.

[19]  J. Peeler,et al.  Premature satellite cell activation before injury accelerates myogenesis and disrupts neuromuscular junction maturation in regenerating muscle. , 2020, American journal of physiology. Cell physiology.

[20]  Devin P. Sullivan,et al.  The human secretome , 2019, Science Signaling.

[21]  Othman Soufan,et al.  NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis , 2019, Nucleic Acids Res..

[22]  H. Okano,et al.  Astrocyte-Derived Exosomes Treated With a Semaphorin 3A Inhibitor Enhance Stroke Recovery via Prostaglandin D2 Synthase , 2018, Stroke.

[23]  G. Neufeld,et al.  Semaphorin-3A inhibits multiple myeloma progression in a mouse model , 2018, Carcinogenesis.

[24]  Thinzar M. Lwin,et al.  MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. , 2018, Tissue & cell.

[25]  H. Okano,et al.  The Semaphorin 3A inhibitor SM-345431 preserves corneal nerve and epithelial integrity in a murine dry eye model , 2017, Scientific Reports.

[26]  D. Nam,et al.  Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth , 2017, Cancer research and treatment : official journal of Korean Cancer Association.

[27]  G. Kéri,et al.  Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers , 2017, PloS one.

[28]  Thinzar M. Lwin,et al.  MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX) , 2017, Oncotarget.

[29]  E. Bongarzone,et al.  SVCT2 Overexpression in Neuroblastoma Cells Induces Cellular Branching that is Associated with ERK Signaling , 2016, Molecular Neurobiology.

[30]  D. V. Von Hoff,et al.  Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells , 2016, PloS one.

[31]  Xiaojie Huang,et al.  Design and Synthesis of Dimeric Securinine Analogues with Neuritogenic Activities. , 2016, ACS chemical neuroscience.

[32]  V. Subramanian,et al.  PA6 Stromal Cell Co-Culture Enhances SH-SY5Y and VSC4.1 Neuroblastoma Differentiation to Mature Phenotypes , 2016, PloS one.

[33]  B. Pasche,et al.  TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. , 2016, Cancer research.

[34]  Claude Chelala,et al.  A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma , 2014, Genome Medicine.

[35]  Chirayu Pankaj Goswami,et al.  PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.

[36]  S. Offermanns,et al.  Semaphorins and plexins as therapeutic targets , 2014, Nature Reviews Drug Discovery.

[37]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[38]  E. Vakiani,et al.  GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling , 2014, Proceedings of the National Academy of Sciences.

[39]  S. Leach,et al.  Sympathetic innervation during development is necessary for pancreatic islet architecture and functional maturation. , 2013, Cell reports.

[40]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[41]  Rashmi Chandra,et al.  Neurohormonal regulation of pancreatic secretion , 2012, Current opinion in gastroenterology.

[42]  L. Zentilin,et al.  Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. , 2012, The Journal of clinical investigation.

[43]  S. McGrath-Morrow,et al.  Semaphorin 3A Contributes to Distal Pulmonary Epithelial Cell Differentiation and Lung Morphogenesis , 2011, PloS one.

[44]  P. Pasricha,et al.  Substance P and calcitonin gene related peptide mediate pain in chronic pancreatitis and their expression is driven by nerve growth factor. , 2011, JOP : Journal of the pancreas.

[45]  Wa Shen,et al.  Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development , 2009, Development.

[46]  L. Zentilin,et al.  Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. , 2009, The Journal of clinical investigation.

[47]  H. Friess,et al.  Association of axon guidance factor Semaphorin 3A with poor outcome in pancreatic cancer , 2007, International journal of cancer.

[48]  A. Kolodkin,et al.  Semaphorin regulation of cellular morphology. , 2007, Annual review of cell and developmental biology.

[49]  H. Friess,et al.  Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells , 2002, Molecular carcinogenesis.

[50]  M. Dickens,et al.  Dual Roles for c-Jun N-Terminal Kinase in Developmental and Stress Responses in Cerebellar Granule Neurons , 2000, The Journal of Neuroscience.

[51]  B. Ruggeri,et al.  Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: Expression patterns and effects on In vitro invasive behavior , 1999, International journal of cancer.

[52]  M. Lai,et al.  Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1. , 2022, American journal of cancer research.

[53]  H. Friess,et al.  Pancreatic neuropathy and neuropathic pain--a comprehensive pathomorphological study of 546 cases. , 2009, Gastroenterology.